- Home
- KTCC vs AGEN Comparison
KTCC vs AGEN Comparison
Compare KTCC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTCC
- AGEN
- Stock Information
- Founded
- KTCC 1969
- AGEN 1994
- Country
- KTCC United States
- AGEN United States
- Employees
- KTCC N/A
- AGEN N/A
- Industry
- KTCC Electrical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KTCC Technology
- AGEN Health Care
- Exchange
- KTCC Nasdaq
- AGEN Nasdaq
- Market Cap
- KTCC 34.0M
- AGEN 38.1M
- IPO Year
- KTCC N/A
- AGEN 2000
- Fundamental
- Price
- KTCC $2.30
- AGEN $1.80
- Analyst Decision
- KTCC
- AGEN Buy
- Analyst Count
- KTCC 0
- AGEN 4
- Target Price
- KTCC N/A
- AGEN $8.00
- AVG Volume (30 Days)
- KTCC 27.6K
- AGEN 519.6K
- Earning Date
- KTCC 05-06-2025
- AGEN 05-06-2025
- Dividend Yield
- KTCC N/A
- AGEN N/A
- EPS Growth
- KTCC N/A
- AGEN N/A
- EPS
- KTCC N/A
- AGEN N/A
- Revenue
- KTCC $514,394,000.00
- AGEN $103,463,000.00
- Revenue This Year
- KTCC N/A
- AGEN $4.03
- Revenue Next Year
- KTCC N/A
- AGEN $5.57
- P/E Ratio
- KTCC N/A
- AGEN N/A
- Revenue Growth
- KTCC N/A
- AGEN N/A
- 52 Week Low
- KTCC $2.25
- AGEN $1.38
- 52 Week High
- KTCC $6.14
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- KTCC 29.20
- AGEN 23.68
- Support Level
- KTCC $2.38
- AGEN $1.46
- Resistance Level
- KTCC $2.70
- AGEN $1.63
- Average True Range (ATR)
- KTCC 0.10
- AGEN 0.11
- MACD
- KTCC 0.01
- AGEN 0.03
- Stochastic Oscillator
- KTCC 8.33
- AGEN 1.22
About KTCC Key Tronic Corporation
Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).